Orange County NC Website
Browse       Search
274 <br />29 CFR Ch. XVII (7–1–10 Edition) §1910.1030 <br />within or as near as possible to the <br />work area. <br />(vi) A ducted exhaust-air ventilation <br />system shall be provided. This system <br />shall create directional airflow that <br />draws air into the work area through <br />the entry area. The exhaust air shall <br />not be recirculated to any other area of <br />the building, shall be discharged to the <br />outside, and shall be dispersed away <br />from occupied areas and air intakes. <br />The proper direction of the airflow <br />shall be verified (i.e., into the work <br />area). <br />(5) Training Requirements. Additional <br />training requirements for employees in <br />HIV and HBV research laboratories and <br />HIV and HBV production facilities are <br />specified in paragraph (g)(2)(ix). <br />(f) Hepatitis B vaccination and post-ex- <br />posure evaluation and follow-up—(1) <br />General. (i) The employer shall make <br />available the hepatitis B vaccine and <br />vaccination series to all employees <br />who have occupational exposure, and <br />post-exposure evaluation and follow-up <br />to all employees who have had an expo- <br />sure incident. <br />(ii) The employer shall ensure that <br />all medical evaluations and procedures <br />including the hepatitis B vaccine and <br />vaccination series and post-exposure <br />evaluation and follow-up, including <br />prophylaxis, are: <br />(A) Made available at no cost to the <br />employee; <br />(B) Made available to the employee <br />at a reasonable time and place; <br />(C) Performed by or under the super- <br />vision of a licensed physician or by or <br />under the supervision of another li- <br />censed healthcare professional; and <br />(D) Provided according to rec- <br />ommendations of the U.S. Public <br />Health Service current at the time <br />these evaluations and procedures take <br />place, except as specified by this para- <br />graph (f). <br />(iii) The employer shall ensure that <br />all laboratory tests are conducted by <br />an accredited laboratory at no cost to <br />the employee. <br />(2) Hepatitis B Vaccination. (i) Hepa- <br />titis B vaccination shall be made avail- <br />able after the employee has received <br />the training required in paragraph <br />(g)(2)(vii)(I) and within 10 working days <br />of initial assignment to all employees <br />who have occupational exposure unless <br />the employee has previously received <br />the complete hepatitis B vaccination <br />series, antibody testing has revealed <br />that the employee is immune, or the <br />vaccine is contraindicated for medical <br />reasons. <br />(ii) The employer shall not make par- <br />ticipation in a prescreening program a <br />prerequisite for receiving hepatitis B <br />vaccination. <br />(iii) If the employee initially declines <br />hepatitis B vaccination but at a later <br />date while still covered under the <br />standard decides to accept the vaccina- <br />tion, the employer shall make avail- <br />able hepatitis B vaccination at that <br />time. <br />(iv) The employer shall assure that <br />employees who decline to accept hepa- <br />titis B vaccination offered by the em- <br />ployer sign the statement in appendix <br />A. <br />(v) If a routine booster dose(s) of hep- <br />atitis B vaccine is recommended by the <br />U.S. Public Health Service at a future <br />date, such booster dose(s) shall be <br />made available in accordance with sec- <br />tion (f)(1)(ii). <br />(3) Post-exposure Evaluation and Fol- <br />low-up. Following a report of an expo- <br />sure incident, the employer shall make <br />immediately available to the exposed <br />employee a confidential medical eval- <br />uation and follow-up, including at least <br />the following elements: <br />(i) Documentation of the route(s) of <br />exposure, and the circumstances under <br />which the exposure incident occurred; <br />(ii) Identification and documentation <br />of the source individual, unless the em- <br />ployer can establish that identification <br />is infeasible or prohibited by state or <br />local law; <br />(A) The source individual’s blood <br />shall be tested as soon as feasible and <br />after consent is obtained in order to de- <br />termine HBV and HIV infectivity. If <br />consent is not obtained, the employer <br />shall establish that legally required <br />consent cannot be obtained. When the <br />source individual’s consent is not re- <br />quired by law, the source individual’s <br />blood, if available, shall be tested and <br />the results documented. <br />(B) When the source individual is al- <br />ready known to be infected with HBV <br />or HIV, testing for the source individ- <br />ual’s known HBV or HIV status need <br />not be repeated. <br />VerDate Mar<15>2010 09:17 Aug 04, 2010Jkt 220114PO 00000Frm 00284Fmt 8010Sfmt 8010Q:\29\29V6.TXTofr150PsN: PC150 <br />DocuSign Envelope ID: 79C5D167-B6CA-4E59-B4AC-AA38CC1B20BD